Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | terminated | Phase 1 | 35 | ADC Therapeutics S.A.INDUSTRY | 1 | May 24, 2021 | clinicaltrials |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | terminated | Phase 1 | 87 | Aptevo TherapeuticsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT01999335 |
| A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma |
| terminated |
| Phase 1 |
| 33 |
| AmgenINDUSTRY |
| 1 |
| Apr 27, 2021 |
| clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | terminated | Phase 1 | 77 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 8, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 21 | Chinook Therapeutics, Inc.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | terminated | Phase 1 / Phase 2 | 9 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT00775268 | 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00521638 | Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 120 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | terminated | Phase 1 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | terminated | Phase 1 / Phase 2 | 25 | Acerta Pharma BVINDUSTRY | 2 | Jan 6, 2021 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | terminated | Phase 1 / Phase 2 | 5 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | terminated | Phase 1 | 2 | Gilead SciencesINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL(DI-Leu16-IL2) | terminated | Phase 1 / Phase 2 | 24 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | terminated | Phase 1 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma(AMETHYST) | terminated | Phase 1 / Phase 2 | 7 | Enceladus Pharmaceuticals BVINDUSTRY | 0 | Nov 6, 2020 | clinicaltrials |
| NCT02937675 | A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 28 | Effector TherapeuticsINDUSTRY | 1 | Nov 2, 2020 | clinicaltrials |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Oct 27, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | terminated | Phase 1 | 9 | IRCCS San RaffaeleOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 7 | Oct 1, 2020 | clinicaltrials |
| NCT02266147 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 29 | Dynavax Technologies CorporationINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | terminated | Phase 1 / Phase 2 | 25 | The Lymphoma Academic Research OrganisationOTHER | 2 | Sep 2, 2020 | clinicaltrials |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | terminated | Phase 1 | 11 | Agios Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis | terminated | Phase 1 | 3 | Tufts Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | University of California, San DiegoOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT00093704 | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | terminated | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 65 | AmgenINDUSTRY | 2 | Jul 13, 2020 | clinicaltrials |
| NCT01551043 | Allo CART-19 Protocol | terminated | Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 5 | Mayo ClinicOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | terminated | Phase 1 | 34 | PfizerINDUSTRY | 3 | Apr 24, 2020 | clinicaltrials |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Cogent Biosciences, Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | terminated | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 24, 2021source: clinicaltrials